Latest News
Via The Motley Fool · March 28, 2025
Via The Motley Fool · March 28, 2025
The S&P 500 Index is off to a challenged start to the year. Many dividend stocks are off to much worse starts year-to-date, which could present value and income investors with some compelling buying opportunities.
Via Talk Markets · March 28, 2025
Does the U.S. market matter more than most?
Via Talk Markets · March 28, 2025
Via Talk Markets · March 28, 2025
Weakening service sector activity and deteriorating consumer confidence have prompted a drop in sentiment across the eurozone.
Via Talk Markets · March 28, 2025
Let's have a look at what is happening on the US markets on Friday. Below you can find the most active S&P500 stocks in today's session.
Via Chartmill · March 28, 2025
Announcing the tariffs in the Oval Office on Thursday, Trump argued that the new measures would create “tremendous growth” in the United States.
Via Talk Markets · March 28, 2025
Via Benzinga · March 28, 2025
Via Benzinga · March 28, 2025
Via Benzinga · March 28, 2025
Curious about the most active stocks on Friday? Find out which stocks are dominating the market action!
Via Chartmill · March 28, 2025
Via The Motley Fool · March 28, 2025
Intel Corporation (NASDAQ: INTC) is undergoing strategic shifts under new CEO Lip-Bu Tan, making ETFs with significant Intel holdings a potential investment opportunity.
Via Benzinga · March 28, 2025
President Donald Trump has pardoned the three co-founders of cryptocurrency exchange BitMEX, who previously pled guilty to federal charges related to money laundering and regulatory violations.
Via Benzinga · March 28, 2025
The anchor underpinning trust in the U.S. monetary system, that is the confidence in the Federal Reserve's ability to keep consumer price changes on track, is facing its most severe test in decades, as inflation expectations spiral.
Via Benzinga · March 28, 2025
The S&P reclaimed its 200 DMA on Monday after comments from the Trump Administration over the weekend about reducing the scope of tariffs.
Via Talk Markets · March 28, 2025
Although Coinbase's imminent death cross seemingly spells trouble, the signal could be a contrarian one for COIN stock.
Via Benzinga · March 28, 2025
Eli Lilly's donanemab faces a setback as EMA's CHMP issues a negative opinion. Analysts expect Lilly to appeal, citing past reversals in similar cases.
Via Benzinga · March 28, 2025
FDA approves Novartis' Pluvicto for advanced prostate cancer patients who have received ARPI therapy.
Via Benzinga · March 28, 2025